Record Status This is a bibliographic record of an ongoing health technology assessment being undertaken by a member of INAHTA. Links to the published report and any other relevant documentation will be added when available. Citation Ipilimumab in combination with dacarbazine within its licensed indication for previously untreated unresectable stage III or IV malignant melanoma (ID74) Health Technology Assessment Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocolss; Dacarbazine; Melanoma Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32013000939 Date abstract record published 12/12/2013 |